<DOC>
	<DOCNO>NCT00327665</DOCNO>
	<brief_summary>As licensed pneumococcal vaccine always satisfactory elderly , new investigational pneumococcal vaccine evaluate healthy elderly population . Note : The study consist primary phase ( 106068 ) : vaccination follow-up extension ( 106072 ) primary phase : 1 year follow-up . This protocol post detail procedure primary &amp; extension phase .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity Investigational Pneumococcal Vaccine Elderly Population</brief_title>
	<detailed_description>No new subject enrol Extension Phase study . All outcome measure Month 12 evaluate subject Belgian site . Upon request , volunteer receive flu vaccination free charge . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female 65 85 year age time first vaccination . Written inform consent obtain subject . Previous vaccination Streptococcus pneumoniae . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Acute disease time enrolment . History document radiologically confirm pneumonia within 3 year prior first vaccination . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine ( ) . Current history Parkinson disease , Alzheimer disease , stroke , dementia serious neurologic mental disorder . All malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . Subjects document anaemia irondeficiency . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 3 month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 2 week first dose vaccine ( ) exception Flu vaccine administer least 1 week precede first dose vaccine ( ) 1 month first dose vaccine ( ) . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History administration experimental/licensed vaccine contain MPL QS21 . History chronic alcohol consumption and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pneumonia</keyword>
	<keyword>pneumococcal vaccine</keyword>
	<keyword>elderly subject</keyword>
	<keyword>invasive pneumococcal disease</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>